Alkermes
ALKS · Pharmaceuticals
$43.63
1.2%ANI Pharmaceuticals
ANIP · Pharmaceuticals
$72.61
1.5%The short version
- Alkermes is the larger business, with $1.5B of revenue in fiscal 2025 against $883M for ANI Pharmaceuticals, about 1.7 times as much.
- ANI Pharmaceuticals grew revenue faster (43.8%, against −5.3%).
- Alkermes kept more of each dollar of sales as operating profit (17.2% operating margin, against 12.6% operating margin).
- Alkermes turned more of its sales into free cash flow (32.6% FCF margin, against 19.4% FCF margin).
- Investors pay more for each dollar of Alkermes’s earnings: a P/E of 114.8x against 15.7x for ANI Pharmaceuticals.
| Latest fiscal year | ALKS · FY25 | ANIP · FY25 |
|---|---|---|
| Size | ||
| Market cap | $7.6B | $1.6B |
| Revenue | $1.5B | $883M |
| Free cash flow | $480M | $171M |
| Net income | $242M | $78.3M |
| Growth | ||
| Revenue growth | −5.3% | 43.8% |
| 5-year growth | 7.3% | 33.5% |
| Share count change | −0.3% | 9.9% |
| Profitability | ||
| Gross margin | 86.7% | — |
| Operating margin | 17.2% | 12.6% |
| Net margin | 16.4% | 8.9% |
| FCF margin | 32.6% | 19.4% |
| Return on capital | — | 15.9% |
| Return on equity | 14.7% | 16.6% |
| Balance sheet | ||
| Net debt | — | $23.7M |
| Net debt / EBITDA | — | 0.1x |
| Dividends and buybacks | $0.0M | $13.4M |
| Valuation & quality | ||
| P/E | 114.8x | 15.7x |
| Piotroski F-score | — | 6 |
FY16
ALKS $746M
ANIP $129M
FY17
ALKS $903M
ANIP $177M
FY18
ALKS $1.1B
ANIP $202M
FY19
ALKS $1.2B
ANIP $207M
FY20
ALKS $1.0B
ANIP $209M
FY21
ALKS $1.2B
ANIP $216M
FY22
ALKS $1.1B
ANIP $316M
FY23
ALKS $1.7B
ANIP $487M
FY24
ALKS $1.6B
ANIP $614M
FY25
ALKS $1.5B
ANIP $883M
ALKS
ANIP
FY16
ALKS −28.0%
ANIP 15.6%
FY17
ALKS −16.4%
ANIP 16.0%
FY18
ALKS −9.1%
ANIP 17.5%
FY19
ALKS −15.0%
ANIP 7.9%
FY20
ALKS −10.8%
ANIP −7.7%
FY21
ALKS 8.3%
ANIP −18.4%
FY22
ALKS −0.6%
ANIP −11.2%
FY23
ALKS 24.9%
ANIP 9.7%
FY24
ALKS 27.0%
ANIP 0.1%
FY25
ALKS 17.2%
ANIP 12.6%
ALKS
ANIP
FY16
ALKS −$107M
ANIP $22.9M
FY17
ALKS −$32.1M
ANIP $29.1M
FY18
ALKS $29.9M
ANIP $61.3M
FY19
ALKS −$18.9M
ANIP $39.0M
FY20
ALKS $40.6M
ANIP $9.1M
FY21
ALKS $73.7M
ANIP $0.8M
FY22
ALKS −$17.2M
ANIP −$40.1M
FY23
ALKS $353M
ANIP $110M
FY24
ALKS $406M
ANIP $47.8M
FY25
ALKS $480M
ANIP $171M
ALKS
ANIP
FY16
ALKS −15.5%
ANIP 5.3%
FY17
ALKS −11.4%
ANIP 5.3%
FY18
ALKS −8.0%
ANIP 11.0%
FY19
ALKS −15.9%
ANIP 5.8%
FY20
ALKS −11.6%
ANIP −3.6%
FY21
ALKS 10.8%
ANIP −7.0%
FY22
ALKS −0.6%
ANIP −5.2%
FY23
ALKS 57.2%
ANIP 8.5%
FY24
ALKS —
ANIP 0.1%
FY25
ALKS —
ANIP 15.9%
ALKS
ANIP
Add another company
Compare up to four at once.
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.